AAAAAA

   
Results: 1-12 |
Results: 12
Pharmacological regulation of postischemic sinusoidal diameters in rats - A new approach for reducing hepatic ischemia/reperfusion injury
Authors: Uhlmann, D Uhlmann, S Loffler, BM Witzigmann, H Spiegel, HU
Citation: D. Uhlmann et al., Pharmacological regulation of postischemic sinusoidal diameters in rats - A new approach for reducing hepatic ischemia/reperfusion injury, CL HEMORH M, 24(4), 2001, pp. 233-246
Severe hypoglycemia due to insulin autoimmune syndrome with autoantibodiescrossreactive to proinsulin
Authors: Lohmann, T Kratzsch, J Kellner, K Witzigmann, H Hauss, J Paschke, R
Citation: T. Lohmann et al., Severe hypoglycemia due to insulin autoimmune syndrome with autoantibodiescrossreactive to proinsulin, EXP CL E D, 109(4), 2001, pp. 245-248
Improvement of postischemic hepatic microhemodynamics by an endothelin converting enzyme inhibitor (FR 901533)
Authors: Uhlmann, D Witzigmann, H Senninger, N Hauss, J Spiegel, HU
Citation: D. Uhlmann et al., Improvement of postischemic hepatic microhemodynamics by an endothelin converting enzyme inhibitor (FR 901533), TRANSPLAN P, 33(4), 2001, pp. 2549-2550
Endothelin converting enzyme protects postischemic liver
Authors: Witzigmann, H Uhlmann, D Senninger, N Hauss, J Spiegel, HU
Citation: H. Witzigmann et al., Endothelin converting enzyme protects postischemic liver, TRANSPLAN P, 33(1-2), 2001, pp. 866-866
Protective role of an endothelin-converting enzyme inhibitor (FR901533) inhepatic ischemia/reperfusion injury
Authors: Uhlmann, D Witzigmann, H Senninger, N Hauss, J Spiegel, HU
Citation: D. Uhlmann et al., Protective role of an endothelin-converting enzyme inhibitor (FR901533) inhepatic ischemia/reperfusion injury, MICROVASC R, 62(1), 2001, pp. 43-54
A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma
Authors: Halm, U Etzrodt, G Schiefke, I Schmidt, F Witzigmann, H Mossner, J Berr, F
Citation: U. Halm et al., A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma, ANN ONCOL, 11(1), 2000, pp. 113-114
Surgery of malignant hepato-biliary tumors
Authors: Hauss, J Witzigmann, H
Citation: J. Hauss et H. Witzigmann, Surgery of malignant hepato-biliary tumors, ZBL CHIR, 125(7), 2000, pp. 577-577
Prognostic impact of proliferation in hepatocellular carcinoma
Authors: Ebelt, J Neid, M Tannapfel, A Witzigmann, H Hauss, J Kockerling, F Wittekind, C
Citation: J. Ebelt et al., Prognostic impact of proliferation in hepatocellular carcinoma, ZBL CHIR, 125(7), 2000, pp. 597-601
Minimal residual disease in primary malignant liver tumors
Authors: Tannapfel, A Geissler, F Witzigmann, H Wittekind, C
Citation: A. Tannapfel et al., Minimal residual disease in primary malignant liver tumors, ZBL CHIR, 125(7), 2000, pp. 602-605
Hepatocellular carcinoma. Resection versus transplantation
Authors: Uhlmann, D Witzigmann, H Geissler, F Tannapfel, A Hauss, J
Citation: D. Uhlmann et al., Hepatocellular carcinoma. Resection versus transplantation, ZBL CHIR, 125(7), 2000, pp. 624-628
Surgical procedure for adenoma of the papilla of Vater
Authors: Witzigmann, H Mobius, C Uhlmann, D Geissler, F Tannapfel, A Halm, U Hauss, J
Citation: H. Witzigmann et al., Surgical procedure for adenoma of the papilla of Vater, CHIRURG, 71(2), 2000, pp. 196-201
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survivaltime in patients with advanced pancreatic cancer
Authors: Halm, U Schumann, T Schiefke, I Witzigmann, H Mossner, J Keim, V
Citation: U. Halm et al., Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survivaltime in patients with advanced pancreatic cancer, BR J CANC, 82(5), 2000, pp. 1013-1016
Risultati: 1-12 |